Miragen Therapeutics Inc – Strategy, SWOT and Corporate Finance Report
- Pages: 48
- Published: July 2019
- Report Code: MLME279932FSA
Miragen Therapeutics Inc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company
Key Highlights
Miragen Therapeutics Inc (miRagen), formerly Signal Genetics Inc is a clinical stage biopharmaceutical company. The company discovers and develops novel RNA-based therapeutics, with a core focus on microRNAs and their roles in diseases. It focuses on hematological malignancies, neuro-degeneration, fibrosis and cardiovascular disease areas. Miragen lead pipeline products candidates are Cobomarsen (MRG-106), an inhibitor of microRNA-155 for treating blood cancers; Remlarsen (MRG-201), a replacement for miR-29 for treating or preventing pathologic fibrosis and MRG-110, an inhibitor of microRNA-92 for treating ischemic conditions. Miragen is headquartered in Boulder, Colorado, the US.
Scope
Detailed information on Miragen Therapeutics Inc required for business and competitor intelligence needs
A study of the major internal and external factors affecting Miragen Therapeutics Inc in the form of a SWOT analysis
An in-depth view of the business model of Miragen Therapeutics Inc including a breakdown and examination of key business segments
News about Miragen Therapeutics Inc, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Miragen Therapeutics Inc and the factors that influence its strategies.Track strategic initiatives of the company and latest corporate news and actions.
Assess Miragen Therapeutics Inc as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Miragen Therapeutics Incs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Regulus Therapeutics Inc
Novartis International AG
Mylan Pharmaceuticals Inc
Merck & Co Inc
Ionis Pharmaceuticals Inc
InteRNA Technologies BV
F. Hoffmann-La Roche Ltd
Dicerna Pharmaceuticals Inc
Celgene Corp
Bristol-Myers Squibb Co
Arrowhead Pharmaceuticals Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple report purchases.